Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infectious Agents and Cancer
Published in: Infectious Agents and Cancer 1/2015

Open Access 01-12-2015 | Research Article

HPV infection and cervical neoplasia: associated risk factors

Authors: Andrea Alves Ribeiro, Maria Cecília Costa, Rosane Ribeiro Figueiredo Alves, Luísa Lina Villa, Vera Aparecida Saddi, Megmar Aparecida dos Santos Carneiro, Luiz Carlos Zeferino, Sílvia Helena Rabelo-Santos

Published in: Infectious Agents and Cancer | Issue 1/2015

Login to get access

Abstract

Background

Behavioral risks such as age at first sexual intercourse, number of sexual partners and partner’s sexual behavior are associated with an increased risk of HPV infection, persistence of the infection and the development of neoplastic precursor lesions. The objective of this study was to evaluate the risk factors associated with HPV positivity and with a diagnosis of cervical neoplasia in women referred with an abnormal cervical smear.

Methods

This study evaluated a series of 198 women referred with an abnormal cervical smear. Risk factors for HPV infection were investigated using a questionnaire. All cervical specimens were tested for 27 HPV genotypes using the Roche polymerase chain reaction reverse line blot assay.

Results

The overall prevalence of HPV was 87 %. First sexual intercourse before 16 years of age was significantly associated with a positive HPV test (OR 4.41; 95 %CI: 1.20 − 19.33; p = 0.01). A significant association was also found between this risk factor and CIN 1 lesions or worse (OR 2.2; 95 %CI 0.94 − 5.08; p = 0.03).

Conclusions

The age at which a woman begins to be sexually active is associated with HPV infection and with a diagnosis of cervical neoplasia.
Literature
1.
Hoory T, Monie A, Gravitt P, Wu TC. Molecular epidemiology of human papillomavirus. J Formos Med Assoc. 2008;107:198–217.PubMedCrossRef
2.
Lenselink CH, Melchers WJG, Quint WGV, Hoebers AMJ, Hendriks JCM, Massuger LFAG, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One. 2008;3, e3743.PubMedCentralPubMedCrossRef
3.
Muñoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugaza I, Gili M, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 1992;52:743–9.PubMedCrossRef
4.
Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.PubMedCentralPubMedCrossRef
5.
Dempsey AF, Mendez D. Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate. J Adolesc Health. 2010;47:242–8.PubMedCentralPubMedCrossRef
6.
Moscicki AB, Ma Y, Wibbelsman C, Powers A, Darragh TM, Farhat S, et al. Risks for cervical intraepithelial neoplasia-3 among adolescents and young women with abnormal cytology. Obstet Gynecol. 2008;112:1335–42.PubMedCentralPubMedCrossRef
7.
Hwang LY, Ma Y, Benningfield SM, Clayton L, Hanson EN, Jay J, et al. Factors that influence the rate of epithelial maturation in the cervix in healthy young women. J Adolesc Health. 2009;44:103.PubMedCentralPubMedCrossRef
8.
Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine. 2008;11:16–36.CrossRef
9.
Ragin CC, Watt A, Markovic N, Bunker CH, Edwards RP, Eckstein S, et al. Compararisons of high-risk cervical HPV infections in Caribean and US populations. Infect Agent Cancer. 2008;4:1–7.CrossRef
10.
Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev. 2006;15:2148–53.PubMedCrossRef
11.
Kulmala SM, Shabalova IP, Petrovitchev N, Syrjänen KJ, Gyllensten UB, Johansson BC, et al. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev. 2007;16:17–22.PubMedCrossRef
12.
Zeferino LC, Derchain SF. Cervical cancer in the developing world. Best Pract Res Clin Obstet Gynaecol. 2006;20:339–54.PubMedCrossRef
13.
Ribeiro AA, Figueiredo Alves RR, Costa MC, Villa LL, Zeferino LC, Mauricette Derchain SF, et al. Association between HPV types and species groups and cervical neoplasia from a high-risk area for cervical cancer, Goiânia, Brazil. Int J Gynecol Pathol. 2011;30:288–94.PubMedCrossRef
14.
Internation Agency for Research on Cancer (IARC). A review of human carcinogens — PartB: biological agents. Monographs on the evaluation of carcinogenic risks to humans. 2012;100B:267-295.
15.
Steenbergen RDM, Snijders PJF, Heideman DAM, Meijer CJLM. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14:395–405.PubMedCrossRef
16.
Scully RE, Bonfiglio TA, Kurman RJ. Histological typing of female genital tract tumors. In: World Health Organization. International Classification of Tumors. 2nd ed. Berlin: Springer; 1994. p. 36–49.
17.
Widdice LE, Moscicki AB. Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents. J Adolesc Health. 2008;43:41–51.CrossRef
18.
Harris RW, Brinton LA, Cowdell RH, Skegg DC, Smith PG, Vessey MP, et al. Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer. 1980;42:359–69.PubMedCentralPubMedCrossRef
19.
Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodríguez AC, Bratti MC, et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res. 2006;66:1218–24.PubMedCrossRef
20.
Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani S, et al. Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer. 2011;21:1654–63.PubMedCrossRef
21.
Mosciscki AB. HPV infections in adolescents. Dis Markers. 2007;23:229–34.CrossRef
22.
Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D, et al. Sexual behaviour in context: a global perspective. Lancet. 2006;368:1706–28.PubMedCrossRef
23.
Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208:152–64.PubMedCrossRef
24.
Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942–53.PubMedCentralPubMed
25.
Mazarico E, Gonzalez-Bosquet E. Prevalence of infection by different genotypes of human papillomavirus in women with cervical pathology. Gynecol Oncol. 2012;125:181–5.PubMedCrossRef
26.
Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjær SK. HPV 16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol. 2012;124:281–5.PubMedCrossRef
27.
Flores YN, Bishai DM, Shah KV, Lazcano-Ponce E, Lörincz A, Hernández M, et al. Risk factors for cervical cancer among HPV positive women in Mexico. Salud Publica Mex. 2008;50:49–58.PubMedCrossRef
28.
Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368–83.PubMedCentralPubMedCrossRef
29.
Cercato MC, Mariani L, Vocaturo A, Carrone A, Terrenato I, Morano G, et al. Predictors of human papilloma virus (HPV) infection in Italian women. J Med Virol. 2010;82:1921–7.PubMedCrossRef
30.
Sarian LO, Hammes LS, Longatto-Filho A, Guarisi R, Derchain SF, Roteli-Martins C, et al. Increased risk of oncogenic human papillomavirus infections and incident high-grade cervical intraepithelial neoplasia among smokers: experience from the Latin American screening study. Sex Transm Dis. 2009;36:241–8.PubMedCrossRef
31.
Yetimalar H, Kasap B, Cukurova K, Yildiz A, Keklik A, Soylu F. Cofactors in human papillomavirus infection and cervical carcinogenesis. Arch Gynecol Obstet. 2012;285:805–10.PubMedCrossRef
Metadata
Title
HPV infection and cervical neoplasia: associated risk factors
Authors
Andrea Alves Ribeiro
Maria Cecília Costa
Rosane Ribeiro Figueiredo Alves
Luísa Lina Villa
Vera Aparecida Saddi
Megmar Aparecida dos Santos Carneiro
Luiz Carlos Zeferino
Sílvia Helena Rabelo-Santos
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2015
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/s13027-015-0011-3

Other articles of this Issue 1/2015

Infectious Agents and Cancer 1/2015 Go to the issue

Research Article

Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study

Research Article

Genetic variability in E6 and E7 oncogenes of human papillomavirus Type 16 from Congolese cervical cancer isolates

Research Article

HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile

Research Article

Prevalence and risk factors for cancer of the uterine cervix among women living in Kinshasa, the Democratic Republic of the Congo: a cross-sectional study

Short Report

Patterns of HIV viremia and viral suppression before diagnosis of non-AIDS-defining cancers in HIV-infected individuals

Letter to the Editor

NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits